The lubricating characteristics of CVTF(continuously variable transmission fluid) mixed with a multi-functional complex additive were studied. The said complex additive contained an organic borate ester and a new type...The lubricating characteristics of CVTF(continuously variable transmission fluid) mixed with a multi-functional complex additive were studied. The said complex additive contained an organic borate ester and a new type of friction improver comprising phosphorus element and poly-methylmethacrylate(PMMA), and a viscosity index improver. The viscosity-pressure characteristics were evaluated by a high-pressure quartz viscometer, and the anti-wear property was investigated by a four-ball friction tester. The mechanism of lubrication by the CVTF was studied using X-ray photoelectron spectroscopy(XPS). The results showed that CVTF T10, which contained a multi-functional complex additive, exhibited excellent properties, featuring greater solidification pressure and pressure-viscosity coefficient, improved oil film strength, and low wear value. These attributes meet the special CVTF requirements for "high friction and low wear" that make it possible to provide both traction and lubrication. The lubricating mechanism was varied using different functional elements, such as inert and active elements. Sulfur and phosphorus are active extreme pressure elements that can react on the metal friction surface and produce an extreme pressure lubrication film. Boron is an inert functional element and does not react upon the metal surface; boron is only adsorbed onto the metal surface to act as a lubricant for adsorption film and fillers.展开更多
The ACE (angiotensin converting enzyme) inhibitors are not only drugs widely prescribed drugs in cardiovascular diseases, but also potentially therapeutic agents in dementia. Based on the findings that the ACE inhib...The ACE (angiotensin converting enzyme) inhibitors are not only drugs widely prescribed drugs in cardiovascular diseases, but also potentially therapeutic agents in dementia. Based on the findings that the ACE inhibitors could activate the c-Jun N-terminal kinase signal to increase the ACE gene expression and that the Alu element of the human ACE gene involved in regulating ACE promoter activity, we aimed to investigate whether there are different pharmacogenetic responses of ACE I/D polymorphism to the ACE inhibitors in neurons. The three reporter vectors, pACEpro(0-SEAP, p-I-ACEpro-SEAP, and p-D-ACEpro-SEAP were used to examine the transcriptional activity of the vectors responding to the lisinopril treatment using a transient-transfection method in SH-SY5Y cells. Our results showed that lisinopril increased the promoter activity of an ACE gene by 16.7%. Additionally, we found the lisinopril enhanced the ACE promoter activity of the I-form vector by 17.2%, but adversely reduced that of the D-form vector by 16.8%, as compared with the respective control without the lisinopril treatment. Firstly, our findings had proved that the UD polymorphism of ACE gene contrarily responds to the ACE inhibitors in regulating the ACE expression in neurons, which provide a novel insight suggesting genetic testing to tailor the treatment regimens in AD (Alzheimer's disease) patients.展开更多
基金financially supported by the China National Machinery Industry Corporation Science & Technology Development Fund (SINOMACH12 No.180)
文摘The lubricating characteristics of CVTF(continuously variable transmission fluid) mixed with a multi-functional complex additive were studied. The said complex additive contained an organic borate ester and a new type of friction improver comprising phosphorus element and poly-methylmethacrylate(PMMA), and a viscosity index improver. The viscosity-pressure characteristics were evaluated by a high-pressure quartz viscometer, and the anti-wear property was investigated by a four-ball friction tester. The mechanism of lubrication by the CVTF was studied using X-ray photoelectron spectroscopy(XPS). The results showed that CVTF T10, which contained a multi-functional complex additive, exhibited excellent properties, featuring greater solidification pressure and pressure-viscosity coefficient, improved oil film strength, and low wear value. These attributes meet the special CVTF requirements for "high friction and low wear" that make it possible to provide both traction and lubrication. The lubricating mechanism was varied using different functional elements, such as inert and active elements. Sulfur and phosphorus are active extreme pressure elements that can react on the metal friction surface and produce an extreme pressure lubrication film. Boron is an inert functional element and does not react upon the metal surface; boron is only adsorbed onto the metal surface to act as a lubricant for adsorption film and fillers.
文摘The ACE (angiotensin converting enzyme) inhibitors are not only drugs widely prescribed drugs in cardiovascular diseases, but also potentially therapeutic agents in dementia. Based on the findings that the ACE inhibitors could activate the c-Jun N-terminal kinase signal to increase the ACE gene expression and that the Alu element of the human ACE gene involved in regulating ACE promoter activity, we aimed to investigate whether there are different pharmacogenetic responses of ACE I/D polymorphism to the ACE inhibitors in neurons. The three reporter vectors, pACEpro(0-SEAP, p-I-ACEpro-SEAP, and p-D-ACEpro-SEAP were used to examine the transcriptional activity of the vectors responding to the lisinopril treatment using a transient-transfection method in SH-SY5Y cells. Our results showed that lisinopril increased the promoter activity of an ACE gene by 16.7%. Additionally, we found the lisinopril enhanced the ACE promoter activity of the I-form vector by 17.2%, but adversely reduced that of the D-form vector by 16.8%, as compared with the respective control without the lisinopril treatment. Firstly, our findings had proved that the UD polymorphism of ACE gene contrarily responds to the ACE inhibitors in regulating the ACE expression in neurons, which provide a novel insight suggesting genetic testing to tailor the treatment regimens in AD (Alzheimer's disease) patients.